Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systems Biology of mRNA COVID-19 Vaccine via Tropis NFIS vs Needle
NCT06919796Phase 2Not yet recruiting
- Sponsor
- PharmaJet
- Start
- May 2025
- Primary completion
- May 2026
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tozinameran in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by PharmaJet. Primary endpoint: Immune Response at 9 months. Planned start May 2025; status: not yet recruiting.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06919796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06919796.